Minerva Surgical, Inc.

$0.00+0.00%(+$0.00)
TickerSpark Score
47/100
Weak
85
Valuation
40
Profitability
15
Growth
64
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UTRS research report →

52-Week Range9% of range
Low $0.00
Current $0.00
High $0.00

Companyminervasurgical.com

Minerva Surgical, Inc. , a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps.

CEO
Darin Hammers
IPO
2021
Employees
174
HQ
Santa Clara, CA, US

Price Chart

-99.00% · this period
$0.00$0.00$0.00May 20Nov 18May 20

Valuation

Market Cap
$888
P/E
-0.00
P/S
0.00
P/B
0.00
EV/EBITDA
-1.63
Div Yield
0.00%

Profitability

Gross Margin
54.17%
Op Margin
-61.44%
Net Margin
-67.83%
ROE
-111.32%
ROIC
-54.33%

Growth & Income

Revenue
$50.29M · -3.47%
Net Income
$-34,112,000 · -58.93%
EPS
$-23.68 · -58.08%
Op Income
$-30,899,000
FCF YoY
-55.21%

Performance & Tape

52W High
$0.00
52W Low
$0.00
50D MA
$0.00
200D MA
$0.00
Beta
4.60
Avg Volume
33

Get TickerSpark's AI analysis on UTRS

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Mar 1, 23Cohen Danielother0
Feb 9, 23NEW ENTERPRISE ASSOCIATES 13 LPbuy24,437,927
Feb 9, 23Accelmed Partners II L.P.other0
Feb 9, 23Geiger Uriother0
Jan 2, 23Usen Toddother0
May 2, 22Skalnyi Evgueni V.other49,755
May 2, 22Filloux Dominique J.other60,198
May 2, 22Jung Joel Rother60,198
May 2, 22Clapper David Mother229,732
Jul 19, 22Sung Derrickother86,956

Our UTRS Coverage

We haven't published any research on UTRS yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate UTRS Report →

Similar Companies